Targeted vectors for cancer immunotherapy

Abstract

This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.

10 - 22 . (canceled) 
     
     
         23 . A targeted retroviral vector particle comprising a modified viral surface protein comprising a collagen binding motif, an immunostimulatory cytokine gene and a cytocidal gene. 
     
     
         24 . The targeted retroviral vector particle of  claim 23 , wherein the immunostimulatory cytokine gene is selected from the group consisting of IL-1, TNF, IL-2, IFN-gamma, IL-7 and GM-CSF. 
     
     
         25 . The targeted retroviral vector particle of  claim 23 , wherein the immunostimulatory cytokine gene is GM-CSF. 
     
     
         26 . The targeted retroviral vector particle of  claim 23 , wherein the cytocidal gene is a mutated cyclin gene, a tumor suppressor gene or a thymidine kinase 
     
     
         27 . The targeted retroviral vector particle of  claim 23 , wherein the cytocidal gene is a thymidine kinase. 
     
     
         28 . The targeted retroviral vector particle of  claim 23 , wherein the collagen binding motif is obtained from von Willebrand coagulation factor. 
     
     
         29 . A pharmaceutical composition comprising the targeted retroviral vector particle of  claim 23 . 
     
     
         30 . The pharmaceutical composition of  claim 29 , further comprising a pharmaceutical excipient. 
     
     
         31 . A method for treating cancer in a subject comprising administering to the subject an effective amount of a pharmaceutical composition of  claim 29 . 
     
     
         32 . The method of  claim 31 , wherein the cancer is a solid tumor. 
     
     
         33 . A targeted retroviral vector particle comprising a modified viral surface protein comprising a collagen binding motif and an immunostimulatory cytokine gene, and a targeted retroviral vector particle comprising a modified viral surface protein comprising a collagen binding motif and a cytocidal gene. 
     
     
         34 . The targeted retroviral particle of  claim 33 , wherein the immunostimulatory cytokine gene is selected from the group consisting of IL-1, TNF, IL-2, IFN-gamma, IL-7 and GM-CSF. 
     
     
         35 . The targeted retroviral vector particle of  claim 33 , wherein the immunostimulatory cytokine gene is GM-CSF. 
     
     
         36 . The targeted retroviral vector particle of  claim 33 , wherein the cytocidal gene is a mutated cyclin gene, a tumor suppressor gene or a thymidine kinase. 
     
     
         37 . The targeted retroviral vector particle of  claim 33 , wherein the cytocidal gene is a thymidine kinase. 
     
     
         38 . The targeted retroviral vector particle of  claim 33 , wherein the collagen binding motif is obtained from von Willebrand coagulation factor. 
     
     
         39 . A pharmaceutical composition comprising the targeted retroviral vector particle of  claim 33 . 
     
     
         40 . The pharmaceutical composition of  claim 39 , further comprising a pharmaceutical excipient. 
     
     
         41 . A method for treating cancer in a subject comprising administering to the subject an effective amount of a pharmaceutical composition of  claim 39 . 
     
     
         42 . The method of  claim 41 , wherein the cancer is a solid tumor.